Literature DB >> 10700186

The gene MAPK8IP1, encoding islet-brain-1, is a candidate for type 2 diabetes.

G Waeber1, J Delplanque, C Bonny, V Mooser, M Steinmann, C Widmann, A Maillard, J Miklossy, C Dina, E H Hani, N Vionnet, P Nicod, P Boutin, P Froguel.   

Abstract

Type 2 diabetes is a polygenic and genetically heterogeneous disease . The age of onset of the disease is usually late and environmental factors may be required to induce the complete diabetic phenotype. Susceptibility genes for diabetes have not yet been identified. Islet-brain-1 (IB1, encoded by MAPK8IP1), a novel DNA-binding transactivator of the glucose transporter GLUT2 (encoded by SLC2A2), is the homologue of the c-Jun amino-terminal kinase-interacting protein-1 (JIP-1; refs 2-5). We evaluated the role of IBi in beta-cells by expression of a MAPK8IP1 antisense RNA in a stable insulinoma beta-cell line. A 38% decrease in IB1 protein content resulted in a 49% and a 41% reduction in SLC2A2 and INS (encoding insulin) mRNA expression, respectively. In addition, we detected MAPK8IP1 transcripts and IBi protein in human pancreatic islets. These data establish MAPK8IP1 as a candidate gene for human diabetes. Sibpair analyses performed on i49 multiplex French families with type 2 diabetes excluded MAPK8IP1 as a major diabetogenic locus. We did, however, identify in one family a missense mutation located in the coding region of MAPK8IP1 (559N) that segregated with diabetes. In vitro, this mutation was associated with an inability of IB1 to prevent apoptosis induced by MAPK/ERK kinase kinase 1 (MEKK1) and a reduced ability to counteract the inhibitory action of the activated c-JUN amino-terminal kinase (JNK) pathway on INS transcriptional activity. Identification of this novel non-maturity onset diabetes of the young (MODY) form of diabetes demonstrates that IB1 is a key regulator of 3-cell function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10700186     DOI: 10.1038/73523

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  51 in total

Review 1.  Defining the genetic contribution of type 2 diabetes mellitus.

Authors:  J van Tilburg; T W van Haeften; P Pearson; C Wijmenga
Journal:  J Med Genet       Date:  2001-09       Impact factor: 6.318

2.  Plasma metabolomic profiles enhance precision medicine for volunteers of normal health.

Authors:  Lining Guo; Michael V Milburn; John A Ryals; Shaun C Lonergan; Matthew W Mitchell; Jacob E Wulff; Danny C Alexander; Anne M Evans; Brandi Bridgewater; Luke Miller; Manuel L Gonzalez-Garay; C Thomas Caskey
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-17       Impact factor: 11.205

Review 3.  The c-jun kinase/stress-activated pathway: regulation, function and role in human disease.

Authors:  Gary L Johnson; Kazuhiro Nakamura
Journal:  Biochim Biophys Acta       Date:  2007-01-04

Review 4.  Molecular etiologies of MODY and other early-onset forms of diabetes.

Authors:  David Q Shih; Markus Stoffel
Journal:  Curr Diab Rep       Date:  2002-04       Impact factor: 4.810

Review 5.  Targeting innate immunity protein kinase signalling in inflammation.

Authors:  Matthias Gaestel; Alexey Kotlyarov; Michael Kracht
Journal:  Nat Rev Drug Discov       Date:  2009-06       Impact factor: 84.694

Review 6.  Promoting longevity by maintaining metabolic and proliferative homeostasis.

Authors:  Lifen Wang; Jason Karpac; Heinrich Jasper
Journal:  J Exp Biol       Date:  2014-01-01       Impact factor: 3.312

7.  Inhibition of membrane depolarisation-induced transcriptional activity of cyclic AMP response element binding protein (CREB) by the dual-leucine-zipper-bearing kinase in a pancreatic islet beta cell line.

Authors:  E Oetjen; A Lechleiter; R Blume; D Nihalani; L Holzman; W Knepel
Journal:  Diabetologia       Date:  2005-12-21       Impact factor: 10.122

8.  Signal transduction cross talk mediated by Jun N-terminal kinase-interacting protein and insulin receptor substrate scaffold protein complexes.

Authors:  Claire L Standen; Norman J Kennedy; Richard A Flavell; Roger J Davis
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

9.  Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes.

Authors:  Judith Miklossy; Hong Qing; Aleksandra Radenovic; Andras Kis; Bertrand Vileno; Forró Làszló; Lisa Miller; Ralph N Martins; Gerard Waeber; Vincent Mooser; Fred Bosman; Kamel Khalili; Nune Darbinian; Patrick L McGeer
Journal:  Neurobiol Aging       Date:  2008-10-23       Impact factor: 4.673

10.  Oxidative stress, ER stress, and the JNK pathway in type 2 diabetes.

Authors:  Hideaki Kaneto; Taka-Aki Matsuoka; Yoshihisa Nakatani; Dan Kawamori; Takeshi Miyatsuka; Munehide Matsuhisa; Yoshimitsu Yamasaki
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.